Intrexon's Q2 Revenues Rise Sharply as Loss Declines | GenomeWeb

NEW YORK (GenomeWeb News) – Synthetic biology firm Intrexon reported after the close of the market Thursday that its second quarter revenues jumped more than 150 percent year over year as the firm trimmed its loss.

The Germantown, Md.-based firm, which went public in early August, brought in total revenues of $6.8 million for the three months ended June 30, up sharply from $2.7 million for the second quarter of 2012.

Its net loss was cut to $6.5 million, or $2.46 per share, from $16.5 million, or $3.99 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.